Tags

Type your tag names separated by a space and hit enter

Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies.
J Prev Alzheimers Dis. 2020; 7(3):158-164.JP

Abstract

Disease-modifying pharmacotherapies for Alzheimer's Disease (AD) are currently in late-stage clinical development; once approved, new healthcare infrastructures and services, including primary healthcare, will be necessary to accommodate a huge demand for early and large-scale detection of AD. The increasing global accessibility of digital consumer electronics has opened up new prospects for early diagnosis and management of mild cognitive impairment (MCI) with particular regard to AD. This new wave of innovation has spurred research in both academia and industry, aimed at developing and validating a new "digital generation" of tools for the assessment of the cognitive performance. In light of this paradigm shift, an international working group (the Global Advisory Group on Future MCI Care Pathways) convened to elaborate on how digital tools may be optimally integrated in screening-diagnostic pathways of AD The working group developed consensus perspectives on new algorithms for large-scale screening, detection, and diagnosis of individuals with MCI within primary medical care delivery. In addition, the expert panel addressed operational aspects concerning the implementation of unsupervised at-home testing of cognitive performance. The ultimate intent of the working group's consensus perspectives is to provide guidance to developers of cognitive tests and tools to facilitate the transition toward globally accessible cognitive screening aimed at the early detection, diagnosis, and management of MCI due to AD.

Authors+Show Affiliations

Marwan N. Sabbagh, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, sabbagm@ccf.org; Tel.: (702) 483-6029; Fax: (702) 722-6584.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32463068

Citation

Sabbagh, M N., et al. "Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported By Emerging Digital Technologies." The Journal of Prevention of Alzheimer's Disease, vol. 7, no. 3, 2020, pp. 158-164.
Sabbagh MN, Boada M, Borson S, et al. Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies. J Prev Alzheimers Dis. 2020;7(3):158-164.
Sabbagh, M. N., Boada, M., Borson, S., Chilukuri, M., Doraiswamy, P. M., Dubois, B., Ingram, J., Iwata, A., Porsteinsson, A. P., Possin, K. L., Rabinovici, G. D., Vellas, B., Chao, S., Vergallo, A., & Hampel, H. (2020). Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies. The Journal of Prevention of Alzheimer's Disease, 7(3), 158-164. https://doi.org/10.14283/jpad.2020.19
Sabbagh MN, et al. Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported By Emerging Digital Technologies. J Prev Alzheimers Dis. 2020;7(3):158-164. PubMed PMID: 32463068.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies. AU - Sabbagh,M N, AU - Boada,M, AU - Borson,S, AU - Chilukuri,M, AU - Doraiswamy,P M, AU - Dubois,B, AU - Ingram,J, AU - Iwata,A, AU - Porsteinsson,A P, AU - Possin,K L, AU - Rabinovici,G D, AU - Vellas,B, AU - Chao,S, AU - Vergallo,A, AU - Hampel,H, PY - 2020/5/29/entrez KW - Alzheimer’s disease KW - cognitive screening KW - digital KW - disease modifying KW - healthcare KW - mild cognitive impairment SP - 158 EP - 164 JF - The journal of prevention of Alzheimer's disease JO - J Prev Alzheimers Dis VL - 7 IS - 3 N2 - Disease-modifying pharmacotherapies for Alzheimer's Disease (AD) are currently in late-stage clinical development; once approved, new healthcare infrastructures and services, including primary healthcare, will be necessary to accommodate a huge demand for early and large-scale detection of AD. The increasing global accessibility of digital consumer electronics has opened up new prospects for early diagnosis and management of mild cognitive impairment (MCI) with particular regard to AD. This new wave of innovation has spurred research in both academia and industry, aimed at developing and validating a new "digital generation" of tools for the assessment of the cognitive performance. In light of this paradigm shift, an international working group (the Global Advisory Group on Future MCI Care Pathways) convened to elaborate on how digital tools may be optimally integrated in screening-diagnostic pathways of AD The working group developed consensus perspectives on new algorithms for large-scale screening, detection, and diagnosis of individuals with MCI within primary medical care delivery. In addition, the expert panel addressed operational aspects concerning the implementation of unsupervised at-home testing of cognitive performance. The ultimate intent of the working group's consensus perspectives is to provide guidance to developers of cognitive tests and tools to facilitate the transition toward globally accessible cognitive screening aimed at the early detection, diagnosis, and management of MCI due to AD. SN - 2426-0266 UR - https://www.unboundmedicine.com/medline/citation/32463068/Rationale_for_Early_Diagnosis_of_Mild_Cognitive_Impairment_(MCI)_Supported_by_Emerging_Digital_Technologies L2 - https://doi.org/10.14283/jpad.2020.19 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.